Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

498.48
-1.8700-0.37%
Post-market: 508.209.72+1.95%18:08 EDT
Volume:488.40K
Turnover:244.64M
Market Cap:21.38B
PE:17.84
High:505.78
Open:500.62
Low:497.67
Close:500.35
52wk High:609.35
52wk Low:397.00
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.62
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.34
PE(LYR):17.89

Loading ...

United Therapeutics CEO Martine Rothblatt Disposes of 9,595 Common Shares Worth $4.98 Million

Reuters
·
Aug 07

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

TIPRANKS
·
Aug 07

United Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 07

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

MT Newswires Live
·
Aug 06

United Therapeutics Corp. : Wells Fargo Cuts Target Price to $700 from $738

THOMSON REUTERS
·
Aug 06

Morgan Stanley Adjusts PT on United Therapeutics to $515 From $516, Maintains Equalweight Rating

MT Newswires Live
·
Aug 06

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

TIPRANKS
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 Loss Widens on Lower Sales, Higher Costs

Reuters
·
Aug 06

United Therapeutics Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

United Therapeutics Q2 Net Income Rises, Revenue Falls

MT Newswires Live
·
Aug 05

United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips

TradingKey
·
Aug 05

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates

Stock Track
·
Aug 05

Earnings Flash (UTHR) United Therapeutics Posts Q2 EPS $7.27, vs. FactSet Est of $6.86

MT Newswires Live
·
Aug 05

United Therapeutics Q2 Revenue USD 783.3 Million Vs. IBES Estimate USD 805.6 Million

Reuters
·
Aug 05

United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M Estimate

Benzinga Earnings
·
Aug 05

United Therapeutics Q2 EPS USD 7.27

THOMSON REUTERS
·
Aug 05

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05